Mankind Pharma Limited (BOM:543904)
India · Delayed Price · Currency is INR 2,562.30
-5.45 (-0.21%)
At close: Aug 1, 2025
Bally's Revenue
Mankind Pharma had revenue of 36.50B INR in the quarter ending June 30, 2025, with 26.16% growth. This brings the company's revenue in the last twelve months to 128.90B, up 21.04% year-over-year. In the fiscal year ending March 31, 2025, Mankind Pharma had annual revenue of 122.07B with 18.98% growth.
Revenue (ttm)
128.90B
Revenue Growth
+21.04%
P/S Ratio
8.22
Revenue / Employee
4.78M
Employees
26,978
Market Cap
1,059.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 122.07B | 19.47B | 18.98% |
| Mar 31, 2024 | 102.60B | 15.11B | 17.27% |
| Mar 31, 2023 | 87.49B | 9.68B | 12.44% |
| Mar 31, 2022 | 77.82B | 15.67B | 25.22% |
| Mar 31, 2021 | 62.14B | 3.43B | 5.83% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,729.85B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,429.39B |
| Infosys | 1,672.76B |
| Hindustan Unilever | 631.21B |